DPYSL2 and neoplasm: Secondly, the exact CRMP2 form which is decreased in tumor cells and thus contributed to disease progression in CRC-DM patients awaits further investigation since the antibodies used in the IHC staining were not able to differentiate f-CRMP2 from s-CRMP2.